Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder

被引:30
|
作者
Amsterdam, Jay D. [1 ]
Williams, David [2 ]
Michelson, David [3 ]
Adler, Lenard A. [4 ]
Dunner, David L. [5 ]
Nierenberg, Andrew A. [6 ]
Reimherr, Frederick W. [7 ]
Schatzberg, Alan F. [8 ]
机构
[1] Univ Penn, Sch Med, Dept Psychiat, Depress Res Unit,Univ Sci Ctr, Philadelphia, PA 19104 USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA
[4] NYU, Dept Psychiat, New York, NY 10016 USA
[5] Ctr Anxiety & Depress, Mercer Isl, WA USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program,Dept Psychiat, Boston, MA USA
[7] Univ Utah, Hlth Sci Ctr, Dept Psychiat, Mood Disorders Clin, Salt Lake City, UT USA
[8] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA
关键词
Tachyphylaxis; Treatment resistant depression; Antidepressant drug therapy; Serotonin reuptake inhibitor; Major depressive disorder; SEROTONIN TRANSPORTER GENE; TREATMENT-RESISTANT DEPRESSION; STAR-ASTERISK-D; LONG-TERM TREATMENT; REUPTAKE INHIBITORS; ALLELIC VARIATION; VENLAFAXINE; EFFICACY; POLYMORPHISM; MIRTAZAPINE;
D O I
10.1159/000226611
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: The aim of this post hoc analysis was to examine whether tachyphylaxis occurs after repeated courses of antidepressant drug therapy. Method: 276 patients with major depressive disorder (MDD) were treated with sertraline (150-200 mg daily) for 8 weeks. Patients with persistent MDD after sertraline therapy were randomized to continuation therapy with either sertraline plus atomoxetine (n = 72) or sertraline plus placebo (n = 74) for 8 additional weeks. Logistic regression was used to test the hypothesis that an increase in prior antidepressant drug exposure is associated with a reduced responsiveness to sertraline therapy. Results: The number of prior antidepressant drug exposures was negatively associated with response to initial sertraline therapy (odds ratio = 0.81, p = 0.0035). The odds ratio indicates a 19.9% reduced likelihood of response with each prior antidepressant treatment trial. In contrast, the number of prior antidepressant treatment trials was not associated with response to continuation sertraline plus atomoxetine or sertraline plus placebo therapy. Conclusion: This observation supports the hypothesis that tachyphylaxis may develop after repeated antidepressant drug trials. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:227 / 233
页数:7
相关论文
共 50 条
  • [1] Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam, Jay D.
    Shults, Justine
    JOURNAL OF AFFECTIVE DISORDERS, 2009, 115 (1-2) : 234 - 240
  • [2] Tachyphylaxis in major depressive disorder: A review of the current state of research
    Kinrys, Gustavo
    Gold, Alexandra K.
    Pisano, Vincent D.
    Freeman, Marlene P.
    Papakostas, George I.
    Mischoulon, David
    Nierenberg, Andrew A.
    Fava, Maurizio
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 245 : 488 - 497
  • [3] Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder
    Liu, Haiyan
    Wang, Chengyu
    Lan, Xiaofeng
    Li, Weicheng
    Zhang, Fan
    Fu, Ling
    Ye, Yanxiang
    Ning, Yuping
    Zhou, Yanling
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [4] Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder
    Kohler-Forsberg, Ole
    Larsen, Erik Roj
    Buttenschon, Henriette N.
    Rietschel, Marcella
    Hauser, Joanna
    Souery, Daniel
    Maier, Wolfgang
    Farmer, Anne
    McGuffin, Peter
    Aitchison, Katherine J.
    Uher, Rudolf
    Mors, Ole
    BRITISH JOURNAL OF PSYCHIATRY, 2019, 215 (02) : 494 - 501
  • [5] Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder
    Ginsberg, Lawrence D.
    CNS SPECTRUMS, 2009, 14 (12) : 8 - 14
  • [6] Rumination in patients with major depressive disorder before and after antidepressant treatment
    Segerberg, Tina S. S.
    Ozenne, Brice
    Dam, Vibeke H.
    Kohler-Forsberg, Kristin
    Jorgensen, Martin B.
    Frokjaer, Vibe G.
    Knudsen, Gitte M.
    Stenbaek, Dea S.
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 360 : 322 - 325
  • [7] Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder
    Hunter, Aimee M.
    Cook, Ian A.
    Tartter, Molly
    Sharma, Simi K.
    Disse, Gregory D.
    Leuchter, Andrew F.
    PSYCHOPHARMACOLOGY, 2015, 232 (20) : 3833 - 3840
  • [8] Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder
    Ghasemi, Mehdi
    Kazemi, Mohammad H.
    Yoosefi, Abolghasem
    Ghasemi, Abbas
    Paragomi, Pedram
    Amini, Homayoun
    Afzali, Mohammad H.
    PSYCHIATRY RESEARCH, 2014, 215 (02) : 355 - 361
  • [9] The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
    Fugger, Gernot
    Bartova, Lucie
    Fabbri, Chiara
    Fanelli, Giuseppe
    Dold, Markus
    Swoboda, Marleen Margret Mignon
    Kautzky, Alexander
    Zohar, Joseph
    Souery, Daniel
    Mendlewicz, Julien
    Montgomery, Stuart
    Rujescu, Dan
    Serretti, Alessandro
    Kasper, Siegfried
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2022, 272 (04) : 715 - 727
  • [10] Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder
    Bayer, TA
    Schramm, M
    Feldmann, N
    Knable, MB
    Falkai, P
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2000, 24 (06) : 881 - 888